Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same

Abstract

An HLA-A*1101-restricted WT1 peptide, specifically, a peptide comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein, wherein the peptide has an ability to bind to an HLA-A*1101 molecule, and has an ability to induce a CTL is described. A peptide dimer having an ability to bind to an HLA-A*1101 molecule and having an ability to induce a CTL, in which two peptide monomers each comprising an amino acid sequence consisting of 9 contiguous amino acids from a WT1 protein and comprising at least one cysteine residue are bound to each other through a disulfide bond is also described. Furthermore, a polynucleotide encoding the peptide, a pharmaceutical composition for the treatment and/or prevention of a cancer comprising the same and the like are provided.

1 - 19 . (canceled) 
     
     
         20 . A method for the induction of a Wilms' tumor 1 (WT1)-specific cytotoxic T cell (CTL), comprising administering to an HLA-A*1101-positive subject an effective amount of an isolated peptide dimer comprising a first and second peptide monomer bound through a disulfide bond, wherein:
 (1) the first peptide monomer consists of the amino acid sequence Thr Gly Val Lys Pro Phe Gln Cys Lys (SEQ ID NO: 7) and   (2) the second peptide monomer consists of the amino acid sequence selected from:   
       
         
           
                 
                 
               
                     
                   (SEQ ID NO: 3) 
                 
                     
                   Pro Ile Leu Cys Gly Ala Gln Tyr Arg, 
                 
                     
                     
                 
                     
                   (SEQ ID NO: 7) 
                 
                     
                   Thr Gly Val Lys Pro Phe Gln Cys Lys, 
                 
                     
                     
                 
                     
                   (SEQ ID NO: 8) 
                 
                     
                   Lys Thr Cys Gln Arg Lys Phe Ser Arg, 
                 
                     
                   and 
                 
                     
                     
                 
                     
                   (SEQ ID NO: 9) 
                 
                     
                   Ser Cys Arg Trp Pro Ser Cys Gln Lys. 
                 
             
                
                
                
                
                
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         21 . The method of  claim 20 , wherein the second peptide monomer consists of the amino acid sequence consists of the amino acid sequence Pro Ile Leu Cys Gly Ala Gln Tyr Arg (SEQ ID NO: 3). 
     
     
         22 . The method of  claim 20 , wherein the second peptide monomer consists of the amino acid sequence consists of the amino acid sequence Thr Gly Val Lys Pro Phe Gln Cys Lys (SEQ ID NO: 7). 
     
     
         23 . The method of  claim 20 , wherein the second peptide monomer consists of the amino acid sequence consists of the amino acid sequence Lys Thr Cys Gln Arg Lys Phe Ser Arg (SEQ ID NO: 8). 
     
     
         24 . The method of  claim 20 , wherein the second peptide monomer consists of the amino acid sequence consists of the amino acid sequence Ser Cys Arg Trp Pro Ser Cys Gln Lys (SEQ ID NO: 9).